My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
0.8788
-0.0107 (-1.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology
September 02, 2021
Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Is ‘Outrageously Fast’ in Oral to Bloodstream Delivery
August 27, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in PCG Report Noting Company Could Deliver for Investors
August 17, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Provides Potential for Significant Cost Savings to Health Care System
August 13, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Well Positioned to Advance Business, Further Execute on Drug-Delivery Goals
August 06, 2021
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability
July 29, 2021
Via
CannabisNewsWire
Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months
July 29, 2021
Image by Lucas Vasques on Unsplash Biotech company Lexaria Bioscience Corp. (NASDAQ: LEXX) has been making news for DehydraTECH™ — its proprietary disruptive and cost-...
Via
Benzinga
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
July 29, 2021
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products
July 28, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
July 28, 2021
Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Supply Chain
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine
July 27, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 27, 2021
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) shares increased by 131.41% to $7.22 during Tuesday's pre-market session. The company's market cap stands at $51.2...
Via
Benzinga
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
July 27, 2021
Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Receives US$3,817,643 From Warrant Exercises
July 26, 2021
KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Test Results Boost Lexaria Bioscience Corp. (NASDAQ: LEXX) Potential in Enhancing Antiviral Drugs
July 23, 2021
Via
CannabisNewsWire
38 Stocks Moving In Thursday's Mid-Day Session
July 22, 2021
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating...
Via
Benzinga
61 Biggest Movers From Yesterday
July 23, 2021
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares jumped 138.2% to close at $13.22 on Thursday after the company announced new results from its TATX-03 PolyTope Therapy...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of Antiviral Drug Studies, Strategy Moving Forward
July 22, 2021
Via
CannabisNewsWire
Topics
Animal Testing
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
July 22, 2021
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Death
Intellectual Property
21 Stocks Moving in Thursday's Pre-Market Session
July 22, 2021
Gainers PainReform Ltd (NASDAQ: PRFX) shares rose 123% to $7.00 in pre-market trading. Second Sight Medical Products Inc (NASDAQ: EYES) shares rose 29% to $5.57 in pre-market...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 21, 2021
Gainers Second Sight Medical (NASDAQ:EYES
Via
Benzinga
Mid-Afternoon Market Update: Dow Jumps 250 Points; Sleep Number Shares Slide After Q2 Results
July 21, 2021
Toward the end of trading Wednesday, the Dow traded up 0.73% to 34,765.42 while the NASDAQ rose 0.66% to 14,594.38. The S&P also rose, gaining 0.69% to 4,352.90. The U.S. has...
Via
Benzinga
Topics
Stocks
61 Biggest Movers From Yesterday
July 22, 2021
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares surged 159.2% to close at $5.34 on Wednesday after the company received a $28.3 million purchase order from Brazil's...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 21, 2021
Gainers Chembio Diagnostics (NASDAQ:CEMI) stock rose 189.72% to $5.97 during Wednesday's regular session. Trading volume for Chembio Diagnostics's stock is 265.3...
Via
Benzinga
Mid-Day Market Update: Crude Oil Up 4%; Chembio Diagnostics Shares Spike Higher
July 21, 2021
Midway through trading Wednesday, the Dow traded up 0.79% to 34,785.02 while the NASDAQ rose 0.59% to 14,584.15. The S&P also rose, gaining 0.70% to 4,353.50. The U.S. has the...
Via
Benzinga
Topics
Stocks
38 Stocks Moving In Wednesday's Mid-Day Session
July 21, 2021
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares jumped 218.7% to $6.57 after the company received a $28.3 million purchase order from Brazil's Bio-Manguinhos to...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Significantly Enhanced Delivery of Colchicine
July 21, 2021
Via
CannabisNewsWire
Mid-Morning Market Update: Markets Open Higher; Coca-Cola Tops Q2 Views
July 21, 2021
Following the market opening Wednesday, the Dow traded up 0.62% to 34,727.53 while the NASDAQ rose 0.40% to 14,557.04. The S&P also rose, gaining 0.52% to 4,345.65. The U.S....
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 21, 2021
Gainers Chembio Diagnostics (NASDAQ: CEMI) shares rose 102.91% to $4.18 during Wednesday's pre-market session. The market value of their outstanding shares is at $84.6 million....
Via
Benzinga
Lexaria Stock Is Trading Higher As DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots
July 21, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The study...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.